4:26 PM
Aug 28, 2012
 |  BC Extra  |  Clinical News

Spinifex's AT2 receptor antagonist meets PHN endpoint

Spinifex Pharmaceuticals Pty. Ltd. (South Yarra, Australia) said EMA401 met the primary endpoint of reducing mean daily pain intensity score from baseline to week four vs. placebo...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >